Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation.
Takuji SeoEmi NoguchiMasayuki YoshidaTaisuke MoriMaki TaniokaKazuki SudoAkihiko ShimomuraKan YonemoriYasuhiro FujiwaraKenji TamuraPublished in: Case reports in oncological medicine (2020)
To the best of our knowledge, this is the first report of BRAF mutation breast cancer treated with dabrafenib and trametinib and it heralds the possibility of targeted therapy for rare breast cancers.